In detail, GLP-1 treatment leads to a decrease in M1 markers, including IL-6, TNF-, and inducible NOS ( i NOS), while promoting increased levels of markers of M2 such as IL-10, arginase-1(Arg-1), macrophage galectin-1 (MGL-1), and mannose receptor-1 (MRC-1) in murine RAW264.7 macrophages [14, 79]
Given that cystic fibrosis is a condition that typically results in malabsorption of fats and other products, it is inferred that subjects with normal gastrointestinal (GI) systems may absorb glutathione effectively at a slightly lower starting dose, proposed to be ~32.5 mg/kg
rectifying reductive stress, as by cyclosporine (137)
doi: 10.1089/thy.2013.0055
National prescription drug spending grew 10% in 2024 alone, and GLP-1 medications are now estimated to account for 14% of all prescription drug spending in 2026